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Background: Carriers of the 2C19*2 loss-of-function allele present higher platelet reactivity and worst clinical outcomes compared to non-
carriers. The hyper-function allele 2C19*17 increases the biotransformation of clopidogrel to its active metabolite. Limited data are available on the 
combined effect of these polymorphisms on platelet reactivity in clopidogrel-treated patients.
Methods:  Following successful PCI, 127 consenting patients were treated with daily 75mg maintenance dose of clopidogrel. On-treatment 
maximal platelet aggregation (MPA) was assessed at 30 days with light transmittance aggregometry after stimulation with 5 μmol/l ADP.
Results Carriers of the *2 allele (n=37) showed higher MPA compared to non-carriers (n=90) [47,1+/-14,6% vs 40,0+/-13,6%; p=0.01]. Carriers 
of the *17 allele (n=42) had lower MPA compared to non-carriers (n=85) [38,1+/-14,3% vs 44,1+/-13,8%; p=0.02]. Patients carrying both the *2 
and *17 alleles (n=11) had a similar MPA when compared to patients exempt from these polymorphisms (n=59) [37,7+/-14.3% vs 41,0+/-13,2%; 
p>0,05], but a lower MPA when compared to carriers of the *2 allele only (n=26) [37,7+/-14.3% vs 51,0+/-12,4%; p=0,001].
Conclusion:Carriers of the *2 polymorphism do not show higher MPA if they simultaneously carry the *17 allele. Since the *17 allele is very 
prevalent in the Caucasian population, concurrent determination of this polymorphism should be performed to better assess the impact of the *2 
polymorphism on platelet reactivity.
